|
|
Article: Afinitor(R) (everolimus) Now Licensed in UK for Advanced Kidney Cancer Patients After Failure of First Line Vascular Targeted Therapy (1,2).
- Article from:
- PR Newswire Europe
- Article date:
- September 24, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FRIMLEY, England, September 24 /PRNewswire/ --
- This Press Release is Intended for Consumer Media Only
- Afinitor More Than Doubles the Median Time Without Tumour Growth and Reduces the Risk of Disease Worsening or Death by 67% Compared With Placebo (2)
- Patients With Advanced Kidney Cancer Have Limited Options Once Tumours Progress After First Line Standard Therapy(3)
- Recently Published UK Expert Clinical Consensus Recommend Afinitor as Second-Line Therapy for Advanced Kidney Cancer Based on Class I Evidence(4)
Afinitor(R) (everolimus) has recently been licensed for the treatment of advanced kidney cancer after failure ...